Zofenopril

Zofenopril
Clinical data
Trade namesZocardis (RU)
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Identifiers
  • (2S,4S)-1-[(2S)-3-benzoylsulfanyl-2-methylpropanoyl]-4-phenylsulfanylpyrrolidine-2-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H23NO4S2
Molar mass429.55 g·mol−1
3D model (JSmol)
  • O=C(N2[C@H](C(=O)O)C[C@H](Sc1ccccc1)C2)[C@H](C)CSC(=O)c3ccccc3
  • InChI=1S/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)/t15-,18+,19+/m1/s1 ☒N
  • Key:IAIDUHCBNLFXEF-MNEFBYGVSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Zofenopril (INN) is a medication that protects the heart and helps reduce high blood pressure. It is an angiotensin-converting enzyme (ACE) inhibitor.[1]

In small studies, zofenopril appeared significantly more effective in reducing hypertension than two older antihypertensive drugs, atenolol and enalapril, and was associated with fewer adverse effects.[2][3]

Zofenopril is a prodrug with zofenoprilat as the active metabolite.[4]

It was patented in 1978 and approved for medical use in 2000.[5]

References

  1. ^ Ambrosioni E (2007). "Defining the role of zofenopril in the management of hypertension and ischemic heart disorders". American Journal of Cardiovascular Drugs. 7 (1): 17–24. doi:10.2165/00129784-200707010-00002. PMID 17355163. S2CID 41320204.
  2. ^ Nilsson P (October 2007). "Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension". Blood Pressure. Supplement. 2: 25–30. doi:10.1080/08038020701561745. PMID 18046976. S2CID 22145457.
  3. ^ Mallion JM (October 2007). "An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension". Blood Pressure. Supplement. 2: 13–18. doi:10.1080/08038020701561703. PMID 18046974. S2CID 27469549.
  4. ^ Subissi A, Evangelista S, Giachetti A (1999). "Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties". Cardiovascular Drug Reviews. 17 (2): 115–133. doi:10.1111/j.1527-3466.1999.tb00008.x.
  5. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 467. ISBN 978-3-527-60749-5.
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.